New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients

NCT ID NCT06367517

Completed Disease control Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether tocilizumab, a drug that calms the immune system, can help people with active moderate-to-severe thyroid eye disease that did not get better with steroids. Thirty-two adults received the drug every four weeks. Researchers measured improvements in eye symptoms and quality of life over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab (also known as RoActemra)
What this could lead to: If successful, this could offer a new treatment option for people with thyroid eye disease who do not respond to standard steroids.
What could go wrong: This was a small, observational study with only 32 participants, so results may not apply to everyone. Tocilizumab can have side effects like infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE MODERATE-TO-SEVERE CORTICOSTEROID-RESISTANT THYROID EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos eye disorder Graves disease Graves Ophthalmopathy hyperthyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPHTHALMOPATHY ORBITOPATHY, GRAVES THYROID EYE DISEASE

Contacts and locations

Locations

Department of Internal Medicine and Endocrinology, Medical University of Warsaw

Warsaw, 02-097, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.